Call for Abstracts EACR 2023 Congress

Deadline Abstract submission: 06 March 2023

Abstracts can only be submitted online.

Abstract Regulations

With the submission of an abstract to the EACR 2023 Congress, the first author (presenting author):

- Accepts responsibility for the accuracy of the submitted abstract.
- Confirms that all authors are aware of and agree to the content of the abstract and support the data presented.
- Warrants that the data and conclusions presented in the abstract have not been published in the same format and with the same title prior to the date of the congress.
- Identifies any financial interest in products or processes described in the abstract. This information is to be forwarded to the Scientific Committee together with the abstract.
- States that, for studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and properly informed consent given where appropriate.
- Gives permission for the abstract, when selected for presentation (oral or poster), to be published in an online supplement to the journal Molecular Oncology, and by the EACR on the Congress website as a PDF proceedings book and through the Congress App.
- Submitted abstracts cannot be withdrawn after 09 May 2023.

Abstract Format

In order to be considered, an abstract should respect the following guidelines:

- The abstract must be submitted in good English. The Scientific Committee reserves the right to reject those abstracts, which are presented in poor English, or may request an immediate revision by the presenter.
- Abstract titles should be brief and should reflect the content of the abstract.
- Commercial names may not be used in the abstract title.
- No more than 10 authors can be listed. Only institutional affiliations, cities and countries should follow.
- Abstracts should be organised under the headings:
  - Introduction
  - Material and method
  - Results and discussion
  - Conclusion
- The online abstract submission procedure will not accept abstracts that exceed 2,500 characters (body of the abstract)
• Abbreviations may be used if standard or if spelled out and defined at the first use. Compounds should be mentioned with the generic name, in lower case. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e. “generic (Commercial ®)
• Supplementary data or appendices will not be accepted.
• Figures or photographs are not allowed. Symbols and structures of drugs are allowed and should be drawn in black and converted to images and inserted as images.

Only the submitting author will receive a confirmation/abstract number by email from the EACR 2023 Customer Service Team within 48 hours of submission. This confirmation of abstract receipt is NOT a notice of acceptance.

For questions regarding the online submission process, please contact our support team via: eacr@newway-management.com

Abstract Selection Process

The Scientific Committee will make the selection of abstracts for oral and poster presentations by 06 April 2023. The presenting author will receive an email with the result of the review and the Scientific Committee's decision on the abstract no later than 06 April 2023. Depending on the selection of presentation format by the committee further instructions on how to prepare posters, or presentation to at Congress will be provided.

If a selected author cannot present, the presenting author should assign a replacement presenter to present the abstract.

The following presentation formats are applicable for EACR 2023 Congress:

1. **Oral presentation:** the abstract is selected for oral presentation in a main Congress symposium
2. **Poster:** abstracts that have been selected for presentation in a poster format. Posters are grouped by (main) topic and displayed during specific Poster Sessions. A formal Poster Defence Session will be scheduled.
3. **Poster in the Spotlight session:** in addition to a poster presentation as above a 'mini oral' presentation is given at a set time in the dedicated moderated Posters in the Spotlight Session in the Spotlight Area located in the poster & exhibition area.

Please note that if the abstract is accepted for oral or poster presentation, the abstract will only be published in the Congress Abstract Publications, if one of the authors is a registered participant to EACR 2023 Congress and full payment has been received by the advised deadline.

If Congress registration has not occurred, the Abstract will not be included in the publications or visible on the Congress Abstract Publications nor will a poster board be made available.
Abstract Submission

Abstract submission procedure
Abstracts must be submitted online by not later than **06 March 2023**, via the EACR 2023 Congress website.

Please follow the instructions on the screen.

Please note:
- When finished with the online submission, please click the **“FINAL SUBMISSION”** button for the final submission of the abstract. As a confirmation of your submission, a message will appear on the screen informing you the abstract has been successfully submitted to our database.
- If you need to edit your abstract at a later stage please click **“SAVE AND CLOSE”**. This button allows you to update your abstract before final submission.
- After clicking “SAVE AND CLOSE”, your abstract is NOT yet submitted. You need to return to the abstract submission page, finalise your abstract and click “FINAL SUBMISSION”. If you have not FINAL SUBMITTED your abstract by the **deadline of 06 March 2023** your abstract can not be accepted.
- Within 24 hours of submission, only the presenting author will receive a confirmation by email. This confirmation of abstract submission does not mean your abstract has been selected for presentation.
- If you do not receive any confirmation, please contact eacr@newway-management.com.
- Submitting an abstract for EACR 2023 Congress does not constitute registration for the Congress. Abstract presenters **must** register to attend EACR 2023 by following the instructions for registration on the EACR 2023 website.

For questions regarding the online submission process, please contact: eacr@newway-management.com

Only abstracts submitted online can be accepted.
Abstracts submitted on paper or as email attachment will unfortunately **not** be considered.
Topics for Abstract Submission

1. **CANCER CELL BIOLOGY**
   - Cell Proliferation/Cell Cycle
   - Cell Death / Autophagy
   - Oncogenes and Tumour Suppressor Genes
   - Metastases and EMT
   - Aging and Cancer
   - Senescence
   - Cancer Cell Metabolism
   - Cancer Initiating Cells / Cancer Stem Cells

2. **CANCER GENOMICS**
   - Genomic Alterations in Cancer
   - Functional Genomics
   - Genomic profiling of Tumours
   - Large-scale Approaches to Cancer Gene Discovery
   - Spatial and 3D Analysis of Tumours
   - oGenomes and Transcriptomes of Cancer at Single Cell Level

3. **EPIGENETICS**
   - DNA Methylation
   - Epigenetic changes as Molecular Markers of Cancer
   - Epigenomics
   - Histone Modification
   - Epigenetic Mechanisms and Gene Silencing
   - Chromatin Structure and Function

4. **BIOINFORMATICS AND COMPUTATIONAL BIOLOGY**
   - Application of Bioinformatics to Cancer Biology
   - Artificial Intelligence and Machine Learning
   - New Algorithms and new Software for Data Analysis
   - Mathematical Modeling and Statistical Methods
   - Molecular Modeling
   - Database Resources and Network Biology
   - Omics Technologies
   - Digital Clinical Trials

5. **TUMOUR EVOLUTION AND HETEROGENEITY**
   - Causes and Consequences of Tumour Heterogeneity
   - Methods to measure Tumour Evolution and Heterogeneity
   - Drug Resistance and Clonal Evolution
6. **DRUG RESISTANCE**
   Novel Mechanisms
   Regulation of Gene Expression in Drug Resistance
   Reversal of Drug Resistance
   Drug Transport and Metabolism
   Resistance to Immune Checkpoint Blockade and other Immune based Therapies

7. **BIOMARKERS IN TISSUE AND BLOOD**
   Liquid Biopsies: Circulating DNA
   Liquid Biopsies: Circulating Tumour Cells
   Diagnostic Biomarkers
   Prognostic Biomarkers
   Biomarkers Predictive of Therapeutic Benefit
   Early Detection Biomarkers

8. **SIGNALING PATHWAYS**
   Receptors and Signal Transduction
   Gene Expression, Transcriptional Regulation
   Systems Biology
   Intracellular Networks
   Computational Models of Biological Systems

9. **CARCINOGENESIS**
   Mutagenesis, Carcinogen Metabolism
   Promotion and Progression
   DNA Damage and Repair
   Viral Oncogenesis

10. **TRANSLATIONAL RESEARCH**
    Organ Site-Specific Investigations: Preclinical, Diagnosis, Treatment
    Molecular Pathology
    Imaging
    Clinical Phase I/II trials with Targeted Drugs and Novel Agents
    Bioinformatics in Therapies and Clinical Trials
    Infrastructures (Biobanks, Databases, Genomic Resources, others)
    Nanotechnologies in Cancer Research

11. **EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS**
    Drug Discovery / Drug Design
    Novel Targets, Delivery Systems
    Mechanisms of Drug Action, Drug Profiling
    New Therapies
    Pharmacogenetics and Therapeutic Response
    Pharmacogenomics
    Pharmacokinetics
Precision Medicine
Target Degradation

12. TUMOUR IMMUNOLOGY
Tumour Immunology
Immune Suppression and Escape
Tumour Antigens and Immune Effectors
Oncogenic Pathway-mediated Deregulation of Tumour Immunity
Antigen Processing and Presentation
Microbiome and Cancer

13. IMMUNOTHERAPY
Adoptive Cell Therapy
Immune Response to Therapies
Immunomodulatory Agents and Interventions
Therapeutic Antibodies, including Engineered Antibodies
Vaccines
Immune Checkpoints
Immune Mechanisms invoked by other Therapies including CARs

14. RADIOBIOLOGY / RADIATION ONCOLOGY
Tumour Cell Sensitisation to Radiotherapy
Radiation-activated Signaling Pathways
Cell Cycle and Apoptosis in Radiation Responses
Radiation Oncology; Preclinical and Clinical
Translational Radiation Research

15. MOLECULAR AND GENETIC EPIDEMIOLOGY
Risk Factors
Risk Assessment
Susceptibility Genes
Genotype / Phenotype Correlations
Genetic Polymorphisms and Cancer Susceptibility
Epidemiology

16. PREVENTION and EARLY DETECTION
Preclinical Prevention Studies, Markers and Prevention
Clinical Prevention Studies
Vaccination Against Cancer
Risk Factors: Heritable and Lifestyle related Risk Factors

17. TUMOUR BIOLOGY
Animal Models of Cancer
Genetic and Genomic Instability
Tumour Progression: Invasion and Metastasis
Tumour Microenvironment
Tumour Angiogenesis
Tumour Inflammation
RNA Biology in Cancer (splicing, noncoding RNAs, RNA modifications) and Therapy Response
Cell Competition
Tumour Dormancy and Persister Cells